


A game changer in surgical wound healing

LAPRIXA consists of:



Anastomotic leak in numbers (EU&US)	
Total number of GI surgeries annually	~2 000 000
AL incidence rate (*dependent on anatomic site and country)	9-16%*
AL mortality rate (*dependent on anatomic site and country)	6-37%*
Average number of AL cases annually	~200 000
Total health care costs of AL complications	~7,3 billion €

Multicenter human clinical trial

Centers that will be involved	MUMC+, NKI-AVL, Amsterdam UMC, Zuyderland MC, Zaanse MC and Spaarne Gasthuis
Number of subjects	710
Start date/end date	03/2021 – 03/2022
Management costs	650 000 €
Material costs	350 000 €
Implementation & submission costs	180 000 €
TOTAL COSTS	1 180 000 €



Contact Details

John Marugg CEO & Alexander Veenhof CSO

+31 43 388 2948

John.marugg@corporis-medical.com

Corporis Medical & LAPRIXA™

Corporis Medical is a young medical device company which started its operations in 2015, focusing on developing innovative solutions for improving access, closure and diagnostic measurements for minimally invasive interventional procedures. The company has several products in development in collaboration with a network of partners (KOL, designers; suppliers; distributors).

LAPRIXA™ is the first and the **smallest tissue blood pressure** measurement device in the world that, unlike others, corrects for general perfusion abnormalities (hyper- or hypotension), providing surgeons with an **immediate patient-customized, objective** reading about the viability of a tissue. The obtained information is crucial in critical decision-making during surgery.

Urgent unmet need in GI surgery

Anastomotic leaks (AL), defined as “a leak of intestinal contents from a surgical join”, is the most feared post-operative complication after gastrointestinal (GI)-surgery. AL translates to re-operations, intensive care admissions, disability, diminished quality of life or even death for many patients. Considering a **10% incidence rate**, with ~ 2 million yearly GI-surgeries performed in Europe and US alone, more than 200.000 cases will suffer from an AL. The health care economic impact exceeds **€7,3 billion annually**, which on average represents a 3-4-fold increase when compared to surgeries without complications.

LAPRIXA™ predicts ~ 90% of ALs

Based on pilot first-in-man clinical trial performed with a first-generation Laprixia™ device, we obtained a Positive Predictive Value (PPV) of ~89% for the occurrence of AL postoperatively. Next steps in the development involve clinical validation by a large randomized multi-center human clinical trial (RCT trial). The PREDICT consortium consisting of **key reference centers and opinion leaders in GI-surgery** in Netherlands such as NKI-AVL (Prof. Dr. G. Beets), Amsterdam UMC (Prof. Dr. D.L. van der Peet), MUMC+ (Prof. Dr. N. Bouvy) and Corporis Medical (**ISO 13485 certified**) was established to prepare, support, and execute the clinical trials.

Co-sponsorship opportunities – what is in it for you?

We are confident that the LAPRIXA™ device will revolutionize the clinical pathway of patients undergoing GI-surgeries by reducing AL. Would you like to support this innovation and gain insights into blood perfusion tissue related wound healing properties?

Co-sponsor the LAPRIXA™ clinical trials in-exchange for access to the obtained clinical data!